Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications ...

Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend this virtual eventR.

Location: (Salons B,C,D - Lower Level, Hilton Chicago) ...

Establishing an innovative class of polyomavirus antivirals spanning BK and JC virus indications CANTON, Mass.--(BUSINESS ...

Verrica Pharmaceuticals Inc. ("Verrica") (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological ...

Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend this virtual eventR. Todd Plott, M.D., Chief Medical Officer, Epiphany Dermatology will join Robert ...

Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune ...

Advancing U.S.-based cGMP manufacturing to support clinical and future commercial objectives of a novel siRNA therapy ...

TAMPA, Fla., April 7, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to ...

A Critical Next Step in Advancing Phio’s PH-762 Program to Treat Cutaneous Carcinomas Phio Pharmaceuticals Corp.

By John Vandermosten, CFA NASDAQ: HURA READ THE FULL HURA RESEARCH REPORT Operational and Financial Results On April 1st, ...

The advent of mRNA vaccines against SARS-CoV-2 in 2020 changed the course of the COVID-19 pandemic. Now, the Nobel ...